Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth

NCT00107029 · View on ClinicalTrials.gov ↗

Study Summary

This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study, "REACH." Blood samples will be collected, a medical and medication history and physical examination will be performed every 6 months for a total of 2 years.

Conditions Studied

Study Locations (10)

Florida

  • Children's Diagnostic and Treatment Center — Fort Lauderdale
  • University of Miami-Jackson Memorial Medical Center — Miami

New York

  • Mount Sinai Medical Center — New York
  • Children's Hospital at Montefiore Medical Center — The Bronx

California

  • Children's Hospital of Los Angeles — Los Angeles

District of Columbia

  • Children's National Medical Center — Washington D.C.

Illinois

  • Cook County Children's Hospital — Chicago

Louisiana

  • Tulane Medical Center — New Orleans

Maryland

  • University of Maryland — Baltimore

Pennsylvania

  • Children's Hospital of Philadelphia — Philadelphia

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2002-12
Est. Completion 2005-09

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00107029

The ClinicalTrials.gov registry entry for NCT00107029 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 725 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00107029 reports 10 study locations spanning 8 distinct geographic areas — top geographies include Florida, New York, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00107029 about?

NCT00107029 is a clinical study titled "Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth". This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study, "REACH." Blood samples will be collected, a medical and medication history and physical exami...

What is the current status of trial NCT00107029?

This trial is currently completed. The enrollment target is 113 participants. The study started on 2002-12. Estimated completion is 2005-09.

What conditions does trial NCT00107029 study?

This clinical trial studies the following conditions: HIV Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT00107029?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 725 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00107029 being conducted?

This trial has 10 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial